Fig. 5

Prognostic value of the DNA methylation signature is independent of TNM stage. a Kaplan-Meier curves for patients with TNM stage I (N = 42). Gastric cancer (GC) patients were stratified by TNM stage (I, II, III, and IV) and the high-risk or low-risk subgroup of patients was determined on the basis of the median risk score. b Kaplan-Meier curves for patients with TNM stage II (N = 117). c Kaplan-Meier curves for patients with TNM stage III (N = 158). d Kaplan-Meier curves for patients with TNM stage IV (N = 28). e Kaplan-Meier estimate of the overall survival (OS) of the entire set GC patients (N = 345) using the DNA methylation signature. GC patients were stratified by TNM stage (I + II and III + IV). f Kaplan-Meier curves for patients with low TNM stage (stage I + II, N = 159). g Kaplan-Meier curves for patients with high TNM stage (stage III + IV, N = 186). The differences between the survival curves were determined by the two-sided log-rank test. h Receiver operating characteristic (ROC) analysis of the sensitivity and specificity of OS prediction by the DNA methylation signature risk score, TNM stage, and combination of the two factors. P values were obtained from the comparisons of the area under the ROC (AUROC) of DNA methylation signature risk score versus those of TNM stage and DNA methylation risk score combined with TNM stage